COMBINATION OF XENON WITH AN NMDA RECEPTOR ANTAGONIST FOR FIGHTING A NEURODEGENERATIVE DISEASE
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jun 2, 2016
app pub date -
Jul 3, 2014
filing date -
Jul 8, 2013
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The invention relates to a gaseous medication containing xenon, preferably in an amount of less than 75% by volume, for use by inhalation, in combination with at least one NMDA receptor antagonist in the form of a liquid or solid, in particular memantine, for treating, slowing or preventing neurological deterioration consequent upon a neurodegenerative disease, in particular Alzheimer's disease, in a human patient.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully